428 related articles for article (PubMed ID: 32508818)
1. IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract][Full Text] [Related]
2. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
[TBL] [Abstract][Full Text] [Related]
3. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
[TBL] [Abstract][Full Text] [Related]
4. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.
Zhang M; Wen B; Anton OM; Yao Z; Dubois S; Ju W; Sato N; DiLillo DJ; Bamford RN; Ravetch JV; Waldmann TA
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10915-E10924. PubMed ID: 30373815
[TBL] [Abstract][Full Text] [Related]
5. A very long-acting IL-15: implications for the immunotherapy of cancer.
Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.
Miljkovic MD; Dubois SP; Müller JR; Bryant B; Ma E; Conlon KC; Waldmann TA
Blood Adv; 2023 Feb; 7(3):384-394. PubMed ID: 35475910
[TBL] [Abstract][Full Text] [Related]
8. IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors.
Chen W; Bamford RN; Edmondson EF; Waldmann TA
Clin Cancer Res; 2022 May; 28(10):2082-2093. PubMed ID: 35262675
[TBL] [Abstract][Full Text] [Related]
9. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.
Zhang M; Yao Z; Dubois S; Ju W; Müller JR; Waldmann TA
Proc Natl Acad Sci U S A; 2009 May; 106(18):7513-8. PubMed ID: 19383782
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-15 in the treatment of cancer.
Waldmann TA
Expert Rev Clin Immunol; 2014 Dec; 10(12):1689-701. PubMed ID: 25359408
[TBL] [Abstract][Full Text] [Related]
13. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1-/low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Chen P; Chen H; Moussa M; Cheng J; Li T; Qin J; Lifson JD; Sneller MC; Krymskaya L; Godin S; Lane HC; Catalfamo M
J Infect Dis; 2020 Feb; 221(4):523-533. PubMed ID: 31562760
[TBL] [Abstract][Full Text] [Related]
15. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
[TBL] [Abstract][Full Text] [Related]
17. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
18. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
Conlon KC; Potter EL; Pittaluga S; Lee CR; Miljkovic MD; Fleisher TA; Dubois S; Bryant BR; Petrus M; Perera LP; Hsu J; Figg WD; Peer CJ; Shih JH; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
Clin Cancer Res; 2019 Aug; 25(16):4945-4954. PubMed ID: 31142503
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 15 as a promising candidate for tumor immunotherapy.
Jakobisiak M; Golab J; Lasek W
Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
